Addressing barriers to successful immunization programs important while vaccine development progresses

Immunizations can be a cost-effective means of disease prevention, but "[t]o reach the fully realized stage of cost-effectiveness, ... it is vital to acknowledge -- and more importantly, address -- the barriers that often prevent them from either being as cheap or as widely used as needed," Forbes contributor Sarika Bansal writes in a Forbes opinion piece. She cites costs associated with vaccines, such as shipping and refrigeration; time and monetary commitments from potential vaccine recipients; a lack of medical professionals in rural areas; and the implementation of public awareness campaigns as barriers to successful immunization campaigns.

"Luckily, many [obstacles] can be overcome with sustained action and a bit of creativity -- and in the case of vaccines, several groups are looking to do just this," Bansal writes, noting efforts by the GAVI Alliance, MIT's Poverty Action Lab and African governments. "While pharmaceutical companies are busy developing and perfecting vaccines ..., other groups should simultaneously improve health systems to allow vaccines to have the strongest possible impact," she concludes (10/25).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Pfizer-BioNTech vaccine provides strong protection against MIS-C in children aged 5–17